Federal health policy has discovered a bold new research method. First, identify an injectable product promoted by wellness influencers. Second, note that scientists want more safety data. Third, label the disagreement ‘medical freedom’ and send it to the White House with excellent posture.

The Department of Health and Human Services submitted an interim access policy for compounded peptides to the Office of Management and Budget for review, according to an official federal regulatory listing posted Wednesday. The filing confirms the proposal exists and remains under review. It does not disclose which substances would qualify or the final terms.

Associated Press reported Thursday that the plan is intended to let specialty pharmacies temporarily compound certain popular peptides under FDA enforcement discretion. People familiar with the deliberations told AP that the list may include BPC-157, promoted online for muscle growth and injury recovery despite not being approved by the FDA for those uses.

That distinction matters because ‘peptide’ is not another word for snake oil. Peptides are part of legitimate, approved medicines, including drugs used for diabetes and weight loss. The issue is whether particular unapproved compounded injections should be sold before there is enough evidence to establish safety and effectiveness. A broad label cannot perform a clinical trial any more than the word ‘vegetable’ can certify a gas-station salad.

FDA staff have warned that some injectable peptides may present risks involving contamination, immune reactions and peptide-related impurities. The agency’s public safety page notes limited human data for several substances. An external advisory panel nevertheless recommended easing restrictions on six of seven peptides it considered this summer, AP reported, departing from the conclusion of FDA staff scientists.

Who Gets The Bill?

Compounding pharmacies and wellness businesses get a larger legal lane into a market AP estimates at $2 billion to $3 billion. Influencers get fresh material for videos recorded beside immaculate dumbbell racks. Political officials get to announce that they liberated medicine from bureaucrats.

Patients get the needle, the uncertainty and whatever happens after the testimonial ends.

Enforcement discretion is a real regulatory tool. Agencies use it when rigid enforcement would create worse outcomes or when circumstances require a temporary bridge. HHS argues that Americans are already purchasing gray-market peptides, including products from overseas, and that supervised compounding may be safer than leaving the market underground. That is not a ridiculous concern.

But ‘people are already buying it online’ cannot become the federal substitute for evidence. By that standard, the government should assign a product code to every supplement advertised between conspiracy podcasts. If gray-market demand is the problem, the policy needs transparent eligibility rules, quality standards, adverse-event reporting and a deadline tied to actual research. Otherwise, temporary discretion has a habit of becoming permanent commerce wearing a lab coat.

The larger political trick is pretending the only choices are paternalistic prohibition or a national injection buffet. Regulators can expand controlled access while still requiring manufacturing safeguards, informed consent and real data. Freedom is not improved when uncertainty is hidden in six-point type and the customer becomes the post-market study.

The influencers have already completed the unboxing. The syringe arrives overnight. The randomized trial is still checking the tracking number.